Exposure to traumatic events can lead to the development of psychiatric conditions, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), substance use disorders, and suicide (Thomas et al., [2010](#CIT0030)). The individual and societal burden of these disorders is enormous. Worldwide, the burden of PTSD alone is estimated at 78 lifetime person-years per 100 individuals in the population (Kessler et al., [2017](#CIT0017)). These figures are even more pronounced in certain groups, such as refugees, where trauma and chronic stress exposure are much higher (Knaevelsrud, Stammel, & Olff, [2017](#CIT0018)). In 2012 alone, the US Department of Veterans Affairs (VA) and Department of Defense (DoD) spent over \$3 billion on the treatment of PTSD in service members and veterans (Institute of Medicine, [2014](#CIT0015)). However, despite the critical need for effective therapy, treatment options and access remain limited (Akiki & Abdallah, [2018a](#CIT0004)).

A better understanding of the neurobiology of trauma-related disorders may be key to advancing effective interventions (Ross et al., [2017](#CIT0029)). Significant resources are being advanced by various funding agencies to enable research in the field. More than ever, it is critical to highlight the potential benefit from such investments. Translational research focusing on the neurobiology of stress-related psychopathology should be framed in the context of the public health burden. While the translational neuroscience and the public health approaches have often been treated as separate subjects (e.g. Akiki, Averill, & Abdallah, [2017](#CIT0007); Fragkaki, Thomaes, & Sijbrandij, [2016](#CIT0011); Frewen, Schmahl, & Olff, [2018](#CIT0012); Lanius & Olff, [2017](#CIT0020); Magruder, Kassam-Adams, Thoresen, & Olff, [2016](#CIT0022); Magruder, McLaughlin, & Elmore Borbon, [2017](#CIT0023)), it is vital to integrate both approaches. Applying a three-tiered prevention model to traumatology (Magruder et al., [2016](#CIT0022)), we highlight ways in which translational neuroscience can pave the way for public health-focused interventions at various levels.

*Primary prevention*, in this context, refers to interventions that target risk factors to mitigate the development of stress- or trauma-related psychopathology. As such, a prerequisite for primary prevention efforts is being able to effectively identify individuals with vulnerability in at-risk subpopulations -- such as first responders and members of the armed forces -- or even in the population at large (when low-cost and effective screening tools become more accessible). Markers of biological risk factors (neural, endocrine, genetic, molecular, etc.) hold significant promise for use in risk stratification, and are likely to complement the more readily measured psychological and social risk factors (Kalisch et al., [2017](#CIT0016)). After identifying individuals who are at increased risk, primary preventive interventions can be implemented either to minimize the risk of trauma exposure in vulnerable individuals (e.g. by limiting workplace-related exposure) or to enhance their resilience to prevent the development of pathology should they be exposed to psychotrauma. While no known biological interventions currently exist in mainstream practice, there are several promising preclinical investigations under way. For example, pretreatment with the *N*-methyl-D-aspartate (NMDA) receptor antagonist ketamine was shown to foster resilience in mice when given 1 week before exposure to models of chronic stress (Brachman et al., [2016](#CIT0008)). While the feasibility and safety of this specific example may not be optimal, such studies are crucial proofs of concept.

*Secondary prevention* strategies, in the classical sense, target individuals exhibiting early signs of illness. In the context of trauma-related disorders, the definition can be adapted to include individuals who have been exposed to trauma, regardless of symptomatology. This group is usually (although not always) easy to target, given the often identifiable timepoint of the index trauma. Secondary preventive interventions could therefore be implemented as part of a post-traumatic prophylaxis framework to target individuals in this acute phase to prevent the development of chronic pathology. Several pharmacotherapies have been proposed and investigated, including classical agents such as beta-adrenergic blockers, corticosteroids, and benzodiazepines (see Abdallah et al., [2018a](#CIT0001), for a recent review). Although there certainly have been early promising works, no consistent beneficial effect has been demonstrated (Akiki & Abdallah, [2018a](#CIT0004)). Nevertheless, several novel investigational approaches have yielded encouraging results. For example, a recent randomized controlled trial of oxytocin revealed benefit in a subgroup with severe (but not mild) PTSD symptoms when administered in the acute phase post-trauma, an effect that was sustained at the 6 month follow-up assessment (van Zuiden et al., [2017](#CIT0031)). The application of brain stimulation approaches in traumatology is still in its infancy, but non-invasive interventions \[e.g. transcranial magnetic stimulation (TMS)\] may hold substantial promise in terms of fostering the robustness of vulnerable neural circuits (Lanius, Frewen, Tursich, Jetly, & McKinnon, [2015](#CIT0021)).

*Tertiary prevention* targets patients with an established psychiatric disorder, with the goal of achieving and maintaining remission, preventing deterioration, enhancing their functional status, and in this context of trauma-related pathology, minimizing the toxic effects of chronic stress. It is the level at which the vast majority of therapeutic interventions are currently being administered, and it is likely to remain an important target point. Current interventions -- psychotherapy and pharmacotherapy -- are limited in their efficacy (Akiki & Abdallah, [2018a](#CIT0004)), which contributes to the public health burden. Ongoing investigations involving rapid-acting antidepressants -- most notably ketamine -- have shown significant promise in robustly and rapidly reducing PTSD and depressive symptoms (Abdallah, Averill, & Krystal, [2015](#CIT0003); Feder et al., [2014](#CIT0009)). Likewise, preliminary studies of drug-augmented psychotherapy with 3,4-methylenedioxymethamphetamine (MDMA) and oxytocin have yielded promising results (Flanagan, Sippel, Wahlquist, Moran-Santa Maria, & Back, [2018](#CIT0010); Mithoefer et al., [2018](#CIT0024)). Neurobiological studies can serve an important role in facilitating the development of rational therapeutics by mapping the mechanistic basis of the disorder (e.g. understanding the neural circuit dysfunction) and developing biomarkers for target validation (Akiki et al., [2018c](#CIT0006); Morey, Haswell, Hooper, & De Bellis, [2015](#CIT0025)). Our recent pharmacoimaging work has found putative *in vivo* neural signatures for response to rapid-acting antidepressants (Abdallah et al., [2018b](#CIT0002)). Similarly, neuroimaging work with oxytocin has also yielded important mechanistic findings (Frijling et al., [2016](#CIT0013)). Even from a public health perspective, where non-selective interventions with potential for broad dissemination are desirable, it is becoming increasingly clear that there is no escape from precision medicine to effectively achieve treatment goals. Identifying neurophysiological subtypes of trauma-related psychopathology may allow for the tailoring of treatments based on specific brain abnormalities that may not be discernible at a phenotypic--behavioural level. The mechanisms underlying the response to brain stimulation approaches such as TMS are only now beginning to be understood (Philip et al., [2018](#CIT0027)). Neuroimaging approaches that respect individual differences in neural circuitry will probably need to be emphasized (Akiki & Abdallah, [2018b](#CIT0005); Nahas, [2010](#CIT0026)). Perhaps the most obvious example at present comes from the field of deep brain stimulation, where subject-specific (Riva-Posse et al., [2018](#CIT0028)) -- but not non-selective (Holtzheimer et al., [2017](#CIT0014)) -- electrode placement was associated with MDD treatment response.

Finally, as we learn more from translational neuroscience, it is important to focus on implementing the findings into policy, and cultural and social norms. For example, if supported by future evidence, policies requiring regular screenings, and limiting the exposures in those at risk can be implemented in first responders. It may also be useful to tackle factors such as exercise, environmental enrichment, and support networks, through social interventions, as they are all known to affect the brain's stress circuitry (Krystal et al., [2017](#CIT0019)). Cultural destigmatization of promising controlled substances (e.g. ketamine and MDMA) will facilitate both access to treatment and research into their potential.

In summary, work on the neurobiology of trauma-related disorders is not only relevant from the point of view of burden on individual patients, but also extremely important and timely from a public health perspective. Improving our understanding of the neurobiology of post-traumatic disorders may be crucial in ushering in an era of improved outcomes for trauma survivors.
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